Pharma Foods International raised its forecast for consolidated ordinary income for the previous fiscal year by 20.0%, from the previous forecast of ¥2.0 billion to ¥2.4 billion. It also raised its ordinary income forecast for the second half to ¥4.83 billion, which is expected to exceed the ¥1.9 billion recorded in the same period a year earlier.
Pharma Foods International announced an earnings forecast revision on the morning of 9 September, raising its forecast for consolidated ordinary income for the fiscal year ending July 2026 from the previous forecast of ¥2.0 billion to ¥2.4 billion. Ordinary income in the previous fiscal year was ¥2.55 billion.
The company said the upward revision reflects improved profitability from the promotion of the New Value Creation 1K Project in the healthcare field, as well as contributions from product rollouts in the BtoB and BtoC fields. Accordingly, its forecast for ordinary income in the second half is expected to be raised from the previous forecast of ¥4.43 billion to ¥4.83 billion, substantially exceeding the ¥1.9 billion recorded in the same period a year earlier.
Under the revised plan for the current fiscal year, second-half revenue is expected to be approximately ¥30.76 billion, ordinary income approximately ¥4.83 billion, net income approximately ¥3.77 billion, and revised earnings per share approximately ¥129.9.